{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-102909","form_type":"8-K","ticker":null,"cik":"0001044378","company_name":"BIOCEPT INC","filed_at":"2023-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.747731+00:00","generated_at":"2026-06-17T01:12:20.629224+00:00","sec_items":["4.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Biocept restates Q1-Q3 2022 results due to errors in stock-based compensation and revenue recognition","bullets":["Errors included incorrect inputs in Black-Scholes calculation for options granted April 2019 and acceleration of stock-based compensation in Q1 2022.","Revenue recognition errors: failure to reflect changes in payor class and implicit price concessions in Q2 and Q3 2022 financial statements.","Management concluded that review controls over stock-based compensation and revenue recognition did not operate effectively, causing material errors.","Restated quarterly financial statements are expected to be filed by April 17, 2023; previously issued Q1-Q3 2022 reports should no longer be relied upon."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-102909","json":"https://secwatch.observer/filing/0001193125-23-102909.json","markdown":"https://secwatch.observer/filing/0001193125-23-102909.md","text":"https://secwatch.observer/filing/0001193125-23-102909.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1044378/000119312523102909/0001193125-23-102909-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1044378/000119312523102909/d496456d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T01:12:20.629224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"81c6234026c1fba129bfe06df704bfcc4080881b","claim":"BIOCEPT INC reported that prior financial statements should not be relied upon.","evidence_excerpt":"nd together with the March 31, 2022 Financial Statements and June 30, 2022 Financial Statements, the “Relevant Financial Statements”) as included in the previously filed Quarterly Reports on Form 10-Q for such quarters, should no longer be relied upon. While preparing the financial statements as of and for the year ended December 31, 2022, the Company discovered that there was an error in the inputs used within the black-scholes calculation for options granted in April 2019. Further, the Company discovered there was an error associated with the acceleration of stock-based compensation recorded in the March 31, 2022 Financial Statements. The Company determined that its review control over the completeness and accuracy of information used when calculating stock-based compensation expense did not operate effectively, resulting in a material error in the March 31, 2022 Financial Statements.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1044378/000119312523102909/0001193125-23-102909-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"non reliance"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}